

## Position Statement

### Varenicline (Champix®) 0.5mg and 1mg tablets for smoking cessation

#### Recommendation:

**Varenicline (Champix®) 0.5mg and 1mg tablets are unavailable until further notice.**

Patients currently prescribed this treatment will require review and **switching to nicotine replacement therapy (NRT) unless contraindicated. No new patients should be initiated on varenicline (Champix®) products.**

**Please note:** Bupropion (Zyban®) is not considered an appropriate alternative for those **clients already using varenicline (Champix®).**

This statement ONLY applies to patients already receiving varenicline, patients new to smoking cessation can receive bupropion first-line according to local arrangements as appropriate.

Helping a patient to stop smoking should not be delayed if they are motivated to stop as other effective options are available.

#### Background:

Pfizer, the sole supplier of varenicline (Champix®), stopped the distribution of all varenicline (Champix®) 0.5mg and 1mg tablets in early June 2021. Pfizer are currently unable to confirm when resupplies will become available following global regulatory investigations relating to the presence of nitrosamine impurities.

Further details are available via:

<https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103160&UNLID=7872921222021101221230>

#### References

1. UK Department of Health and Social Care. Supply Disruption Alert SDA/2021/006. Champix® (varenicline) 0.5mg and 1mg tablets – Supply Disruption. Issued 24<sup>th</sup> June 2021. Available via: <https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103160&UNLID=7872921222021101221230> [accessed online: 01/11/21].
2. National Centre for Smoking Cessation and Training. Switching from varenicline (Champix) to an alternative stop smoking medication. Accessed via <https://www.ncsct.co.uk/usr/pub/Guidance%20on%20switching%20from%20Champix.pdf> [accessed online: 05/11/2021].

**Please access this guidance via the LSCMMG website to ensure that the correct version is in use.**

#### Version Control

Version Number	Date	Amendments Made	Author
Version 1.0	November 2021	New document.	AG
Version 1.1	July 2022	Position clarified for new patients.	AG

©Midlands and Lancashire Commissioning Support Unit, 2022.

The information contained herein may be superseded in due course. All rights reserved.  
Produced for use by the NHS, no reproduction by or for commercial organisations, or for commercial purposes, is allowed without express written permission.  
Midlands and Lancashire Commissioning Support Unit,  
Jubilee House, Lancashire Business Park, Leyland, PR26 6TR  
Tel: 01772 644 400 | [www.midlandsandlancashirecsu.nhs.uk](http://www.midlandsandlancashirecsu.nhs.uk)